Home Alzheimer’s Disease Treatment With Adjuvant Osimertinib Improves DFS for Patients With EGFR-mutated NSCLC

Treatment With Adjuvant Osimertinib Improves DFS for Patients With EGFR-mutated NSCLC

An exploratory analysis of the pivotal phase 3 ADAURA trial (NCT02511106) found that treatment with adjuvant osimertinib (Tagrisso) led to improved disease-free survival (DFS) for patients with EGFR-mutated non-small cell lung cancer (NSCLC), irrespective of prior adjuvant chemotherapy received or disease stage, according to results presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC).1

In the overall patient population, adjuvant osimertinib resulted in an 84% reduction in the risk of disease recurrence or death in patients who had previously received adjuvant chemotherapy (HR, 0.16; 95% CI, 0.10-0.26); the reduction was slightly lower, at 77% (HR, 0.23; 95% CI, 0.13-0.40), in those who had not received chemotherapy. Notably, the DFS benefit achieved with adjuvant osimertinib proved to be comparable across all stages of…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments